Cryosite Limited (CTE) AI Stock Analysis

• Market Cap: AU$40.76M
• Dividend Yield: 2.4%
• Average Volume (3M): 2.23K
• Price to Earnings (P/E): 21.6
• Beta (1Y): -0.54
• Revenue Growth: 11.93%
• EPS Growth: 2.39%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.02
• Shares Outstanding: 48,809,563
• 10 Day Avg. Volume: 291
• 30 Day Avg. Volume: 2,228
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.00
• Price Target Upside: 19.05% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 66 Neutral
• Price Target: AU$1.00 ▲(19.05% Upside)

Cryosite Limited's overall stock score is driven by strong financial performance and an attractive dividend yield. The technical analysis indicates bullish momentum, but the high RSI suggests caution due to potential overbought conditions. The valuation is mixed, with a high P/E ratio offset by a strong dividend yield. The absence of earnings call and corporate events data limits additional insights.

Cryosite Limited Business Overview & Revenue Model

Company Description

Cryosite Limited (CTE) is an Australian company operating in the biotechnology and life sciences sector. The company primarily focuses on the storage and management of biological materials, including cord blood and tissue, which are used in medical treatments and research. Cryosite offers specialized storage solutions and logistics services to healthcare providers, research institutions, and individuals, ensuring the safe and secure preservation of biological specimens.

How the Company Makes Money

Cryosite Limited generates revenue through its specialized storage services for biological materials. The company charges fees for the collection, processing, and long-term storage of cord blood and tissue, which are critical for potential future medical use. Cryosite also provides logistics and distribution services for clinical trials and other scientific research, partnering with pharmaceutical companies and research organizations. These services encompass the secure transportation and management of biological specimens, contributing significantly to the company's income. Key revenue streams include storage fees, processing fees, and service charges for logistics solutions. Additionally, Cryosite may engage in partnerships with healthcare providers and research institutions to expand its service offerings and client base.

Cryosite Limited Financial Statement Overview

Summary

Cryosite Limited exhibits strong revenue growth and profitability, supported by efficient operations. The balance sheet is stable with manageable leverage, though the reliance on debt could be a risk factor. Cash flow performance is mixed, with declining free cash flow growth being a potential concern. Overall, the company is in a solid financial position but should focus on improving cash flow generation.

Income Statement

Cryosite Limited has demonstrated consistent revenue growth, with a notable 9.85% increase in the latest year. The company maintains strong profitability metrics, with a gross profit margin of 62.98% and a net profit margin of 13.35%. EBIT and EBITDA margins are healthy, indicating efficient operations. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.95, indicating manageable leverage. Return on equity is robust at 78.86%, reflecting effective use of equity to generate profits. However, the equity ratio is relatively low, suggesting a higher reliance on debt financing, which could pose risks if not managed carefully.

Cash Flow

The cash flow statement reveals a decline in free cash flow growth by 32.88%, which is a concern. The operating cash flow to net income ratio is below 1, indicating that not all earnings are being converted into cash. The free cash flow to net income ratio of 71.61% suggests a reasonable conversion of profits into free cash flow, but the declining trend in free cash flow growth warrants attention.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.85M	14.12M	12.61M	11.94M	11.76M	10.02M
Gross Profit	7.89M	8.89M	7.99M	6.48M	6.27M	5.31M
EBITDA	3.21M	3.41M	3.04M	2.34M	2.45M	1.65M
Net Income	1.83M	1.88M	1.84M	1.41M	1.36M	652.57K
Balance Sheet
Total Assets	19.09M	19.46M	19.71M	22.65M	21.50M	21.99M
Cash, Cash Equivalents and Short-Term Investments	4.49M	5.06M	4.70M	5.73M	5.34M	3.88M
Total Debt	2.36M	2.27M	2.44M	2.61M	849.76K	1.07M
Total Liabilities	17.77M	17.07M	18.26M	19.86M	19.64M	21.17M
Stockholders Equity	1.31M	2.39M	1.45M	2.78M	1.86M	819.23K
Cash Flow
Free Cash Flow	2.20M	1.48M	2.44M	1.19M	1.63M	80.07K
Operating Cash Flow	2.76M	2.06M	2.90M	1.49M	2.49M	476.96K
Investing Cash Flow	-561.00K	-420.00K	727.00K	-1.33M	-863.19K	-396.89K
Financing Cash Flow	-3.72M	-1.29M	-3.50M	-768.00K	-148.99K	-260.78K

Cryosite Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Positive. The current price of 0.84 is below the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.78, and above the 200-day MA of 0.77, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 61.91 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CTE.

Cryosite Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	66 Neutral	AU$40.76M	21.63	98.18%	2.40%	11.93%	2.39%
LDX	55 Neutral	AU$121.81M	-10.47	―	―	12.96%	45.59%
IIQ	49 Neutral	AU$47.44M	-6.82	―	―	2.33%	12.50%
RHY	45 Neutral	AU$29.65M	-6.98	―	―	―	56.42%
BDX	43 Neutral	AU$25.62M	-3.54	―	―	―	23.85%
MAP	41 Neutral	AU$49.33M	-2.43	―	―	29.60%	33.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Cryosite Limited Corporate Events

Cryosite Limited Transitions to New Share Registry Provider

Cryosite Limited has announced a change in its shareholder registry service provider from MUFG Investor Services to Automic Pty Ltd, effective from July 14, 2025. This transition aims to enhance shareholder experience by offering a secure and accessible online portal for managing holdings, updating details, and viewing transaction history, potentially improving operational efficiency and stakeholder engagement.

Cryosite Director Increases Stake with New Share Acquisition

Cryosite Limited has announced a change in the director’s interest in securities. Mark Kerr, a director of the company, has acquired 75,000 fully paid ordinary shares through on-market purchases, increasing his total holdings. This acquisition reflects a continued investment by the director in the company, potentially signaling confidence in the company’s future performance.